Immune Signatures Identify Patient Subsets Deriving Long‐Term Benefit From First‐Line Rituximab in Follicular Lymphoma

Immune Signatures Identify Patient Subsets Deriving Long‐Term Benefit From First‐Line Rituximab in Follicular Lymphoma

ABSTRACT Background The role of first‐line single‐agent rituximab immunotherapy in follicular lymphoma (FL) remains debated, as most patients eventually undergo chemotherapy. Methods In this study, we retrospectively analyzed 81 FL patients treated with first‐line single‐agent rituximab monotherapy...

Full description

Bibliographic Details
Main Authors: Ginevra Lolli, Alessandro Davini, Valentina Tabanelli, Maria Rosaria Sapienza, Federica Melle, Giovanna Motta, Marcello Del Corvo, Angelica Calleri, Anna Vanazzi, Paulina Nierychlewska, Alessio Maria Edoardo Maraglino, Marta Castelli, Maria Chiara Quattrocchi, Roberto Chiarle, Stefano Pileri, Corrado Tarella, Enrico Derenzini
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:eJHaem
Online Access:https://doi.org/10.1002/jha2.1103

Internet

https://doi.org/10.1002/jha2.1103

Similar Items